Enimmune corporation reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was TWD 13 million compared to TWD 92.09 million a year ago. Net loss was TWD 77.71 million compared to TWD 155.79 million a year ago.

Basic loss per share from continuing operations was TWD 1.18 compared to TWD 2.52 a year ago. Diluted loss per share from continuing operations was TWD 1.18 compared to TWD 2.52 a year ago.